Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1901 1
1902 1
1903 4
1905 1
1906 2
1907 1
1912 1
1914 1
1915 1
1916 1
1919 1
1920 1
1921 1
1925 1
1927 1
1928 1
1929 1
1932 1
1934 1
1937 1
1964 1
1971 1
1974 2
1975 1
1976 1
1977 1
1979 2
1981 2
1982 1
1983 1
1984 1
1986 1
1992 2
1993 1
1994 1
1995 1
1996 3
1998 2
1999 3
2000 2
2001 3
2002 3
2004 4
2005 3
2006 4
2007 10
2008 11
2009 16
2010 13
2011 10
2012 6
2013 3
2014 13
2015 15
2016 14
2017 24
2018 22
2019 27
2020 29
2021 44
2022 37
2023 68
2024 66
2025 68
2026 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

528 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes in IgA Nephropathy.
Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Pitcher D, et al. Among authors: barratt j. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13. Clin J Am Soc Nephrol. 2023. PMID: 37055195 Free PMC article.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Among authors: barratt j. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
The pathogenesis of IgA nephropathy and implications for treatment.
Cheung CK, Alexander S, Reich HN, Selvaskandan H, Zhang H, Barratt J. Cheung CK, et al. Among authors: barratt j. Nat Rev Nephrol. 2025 Jan;21(1):9-23. doi: 10.1038/s41581-024-00885-3. Epub 2024 Sep 4. Nat Rev Nephrol. 2025. PMID: 39232245 Free PMC article. Review.
IgA nephropathy.
Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, Barratt J, Kramann R. Stamellou E, et al. Among authors: barratt j. Nat Rev Dis Primers. 2023 Nov 30;9(1):67. doi: 10.1038/s41572-023-00476-9. Nat Rev Dis Primers. 2023. PMID: 38036542 Review.
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk DV; APPLAUSE-IgAN Investigators. Perkovic V, et al. Among authors: barratt j. N Engl J Med. 2025 Feb 6;392(6):531-543. doi: 10.1056/NEJMoa2410316. Epub 2024 Oct 25. N Engl J Med. 2025. PMID: 39453772 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: barratt j. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Atrasentan in Patients with IgA Nephropathy.
Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J; ALIGN Study Investigators. Heerspink HJL, et al. Among authors: barratt j. N Engl J Med. 2025 Feb 6;392(6):544-554. doi: 10.1056/NEJMoa2409415. Epub 2024 Oct 25. N Engl J Med. 2025. PMID: 39460694 Clinical Trial.
IgA nephropathy in adults-treatment standard.
Gleeson PJ, O'Shaughnessy MM, Barratt J. Gleeson PJ, et al. Among authors: barratt j. Nephrol Dial Transplant. 2023 Oct 31;38(11):2464-2473. doi: 10.1093/ndt/gfad146. Nephrol Dial Transplant. 2023. PMID: 37418237 Free PMC article. Review.
IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.
Vivarelli M, Samuel S, Coppo R, Barratt J, Bonilla-Felix M, Haffner D, Gibson K, Haas M, Abdel-Hafez MA, Adragna M, Brogan P, Kim S, Liu I, Liu ZH, Mantan M, Shima Y, Shimuzu M, Shen Q, Trimarchi H, Hahn D, Hodson E, Pfister K, Alladin A, Boyer O, Nakanishi K; International Pediatric Nephrology Association. Vivarelli M, et al. Among authors: barratt j. Pediatr Nephrol. 2025 Feb;40(2):533-569. doi: 10.1007/s00467-024-06502-6. Epub 2024 Sep 27. Pediatr Nephrol. 2025. PMID: 39331079 Free PMC article.
528 results